PMTI Palomar Medical Technologies, Inc. (MM)

BURLINGTON, Mass., March 28 /PRNewswire-FirstCall/ -- Palomar Medical Technologies Inc. (NASDAQ:PMTI), a leading researcher and developer of light- based systems for cosmetic treatments, announced today that it will unveil its latest innovation in aesthetic laser technology at the 28th annual conference of the American Society for Laser Medicine & Surgery (ASLMS) in Kissimmee Florida, April 2-6. Palomar will display a new platform called the Aspire(TM) aesthetic laser platform and Stylus(TM) Sculpter laser-assisted liposuction handpiece in booth #507 in the ASLMS exhibit hall. The Aspire platform will allow Palomar to offer solutions to new procedures which are in high-demand including laser-assisted liposuction. The Aspire platform will complement the broad range of aesthetic applications offered by Palomar's flagship StarLux(R) 500 laser and pulsed-light platform. Traditional liposuction is one of the most commonly performed plastic surgery procedures, according to the 2007 survey from the American Society of Aesthetic Plastic Surgery. Laser-assisted liposuction holds out the promise for a better technique due to the laser's ability to quickly and selectively melt fat and heat surrounding tissue. Palomar's approach to laser-assisted liposuction with the Aspire platform and Stylus Sculpter handpiece is to utilize unique tip designs and selective and efficient wavelengths for melting fat and providing the desired thermal effects on surrounding tissue. Chief Executive Officer Joseph P. Caruso commented, "The unveiling of the Aspire platform and Stylus Sculpter handpiece is the culmination of years of research directed to absorption of light by fat. Our system uses optimal wavelengths to melt fat and provide the appropriate amount of heat to the surrounding tissue. As with all Palomar products, the Aspire platform is based on sound scientific principles developed and tested by Palomar's research and development organization, which is preeminent in the light-based aesthetic industry." Mr. Caruso continued, "The Aspire platform is an ideal complement to the StarLux platform for providing opportunities for even more treatment modalities. With the new aesthetic procedures that will be possible with Aspire, and the many popular treatments, including hair removal, skin rejuvenation and skin resurfacing, available with the StarLux(R) 500, practitioners will be able to offer a complete suite of the most-requested aesthetic procedures." The Aspire Platform and Stylus Sculpter liposuction laser-assisted handpiece are pending FDA clearance and should be available for shipment in the third quarter. In addition to the introduction of the Aspire platform, the following presentations at ASLMS are relevant to Palomar technology: April 4, 2008 -- Randomized Study of Intense Pulsed Light and Pulsed Dye Laser in the Treatment of Facial Telangiectasia. 2:24 pm - 2:29 pm (The Sun AB Room) -- Long-Term Experience with Fixed Array 1540 Fractional Erbium Laser for Acne Scars. 3:54 pm - 3:59 pm (The Sun AB Room) -- Ablative Micro-Fractional Resurfacing: Time-Course Histology and Clinical Correlations. 4:23 pm - 4:28 pm (The Sun AB Room) -- Use of a Micro-Fractional 2940 NM Laser in the Treatment of Wrinkles and Dyspigmentation. 5:12 pm - 5:17 pm (The Grapevine B Room) April 5, 2008 -- Self Canalization of Laser Microbeam in Tissue as Fundamental Mechanism of Fractional Skin Resurfacing. 4:51 pm - 4:58 pm (The Sun AB Room) April 6, 2008 -- Deep Infrared Light for Skin Tightening Combined with 1540NM Fractional Resurfacing -- Split-Face Study. 8:20 am - 8:25 am (The Sun AB Room) About Palomar Medical Technologies Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the- counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne. For more information on Palomar and its products, visit Palomar's website at http://www.palomarmedical.com/ . To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website. This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current expectations, plans, intentions, beliefs or predictions. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2007 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Contacts: Kayla Castle Investor Relations Manager Palomar Medical Technologies, Inc. 781-993-2411 DATASOURCE: Palomar Medical Technologies Inc. CONTACT: Kayla Castle, Investor Relations Manager of Palomar Medical Technologies, Inc., +1-781-993-2411, Web site: http://www.palomarmedical.com/ Company News On-Call: http://www.prnewswire.com/comp/107555.html

Copyright